Is PT-141 (Bremelanotide) Legal in Massachusetts?

What PT-141 (Bremelanotide) Actually Is

PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone. The FDA approved it under the brand name Vyleesi on June 21, 2019, making it the second drug ever cleared for HSDD in premenopausal women, following flibanserin (Addyi) in 2015 [1]. Unlike sildenafil or tadalafil, which act on vascular smooth muscle, bremelanotide acts centrally. It binds melanocortin receptors MC3R and MC4R in the hypothalamus to modulate sexual desire at the neurochemical level [2].

Mechanism and Pharmacology

The drug is delivered as a single-use autoinjector into the abdomen or thigh. Peak plasma concentration occurs roughly 1 hour after injection, and the half-life is approximately 2.7 hours [1]. Because it works upstream of arousal rather than on blood flow, it does not require sexual stimulation to initiate its effect.

Bremelanotide also carries a meaningful side-effect profile. Nausea affects roughly 40% of users in clinical trials, and transient blood pressure increases (mean peak increase of approximately 6 mmHg systolic) occur within 12 hours of dosing in most patients [1]. The FDA therefore contraindicated it in patients with cardiovascular disease or uncontrolled hypertension [1].

Clinical Evidence Base

The Reconnect program consisted of two randomized, double-blind, placebo-controlled Phase 3 trials (Study 301 and Study 302) in a pooled population of 1,247 premenopausal women with HSDD [3]. Women receiving bremelanotide 1.75 mg reported statistically significant increases in the number of satisfying sexual events and statistically significant decreases in distress scores on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) compared with placebo at 24 weeks [3]. The between-group difference on the FSDS-DAO item 13 distress score was approximately 0.3 points, reaching P<0.001 [3].

The FDA's approval label states: "The efficacy of Vyleesi was established in two randomized, double-blind, placebo-controlled 24-week trials in premenopausal women with acquired, generalized HSDD" [1].

Federal Legal Framework for PT-141

Understanding Massachusetts law requires understanding federal law first, because state rules layer on top of the federal baseline.

FDA Approval and Prescription Status

Bremelanotide holds full FDA approval as a New Drug Application (NDA) product [1]. This means it is a legal prescription drug in all 50 states when dispensed pursuant to a valid prescription from a licensed prescriber. It is not a controlled substance under the Controlled Substances Act [4]. The DEA does not schedule it, so prescribers do not need a DEA number specifically for bremelanotide, though they need one to maintain a general DEA registration [4].

Buying or selling bremelanotide without a prescription violates the Federal Food, Drug, and Cosmetic Act (FD&C Act), specifically 21 U.S.C. § 331, which prohibits the introduction of misbranded or unapproved new drugs into interstate commerce [5].

Compounding Under 503A and 503B

Because Vyleesi's list price can exceed $900 per dose, many patients ask whether a compounding pharmacy can legally prepare a less expensive version. The answer is nuanced.

Under Section 503A of the FD&C Act, a state-licensed compounding pharmacy may prepare a drug from bulk active pharmaceutical ingredients (APIs) for a specific patient when a valid prescription exists, provided the drug is not on the FDA's Bulks Prohibition List and the final preparation does not appear on the FDA's List of Drugs That Present Demonstrable Difficulties for Compounding [5]. As of the date of this article, bremelanotide does not appear on the FDA's final Bulks Prohibition List [6].

Under Section 503B, outsourcing facilities can compound larger batches without patient-specific prescriptions, but the same bulk-substance rules apply and the facility must be FDA-registered [5].

The FDA has signaled ongoing scrutiny of peptide compounding broadly. In 2024, the agency finalized a rule placing several compounded peptides on the Bulks Prohibition List, though bremelanotide was not among those specifically listed at the time of this writing [6]. Clinicians and pharmacies should verify current list status before prescribing or dispensing compounded bremelanotide because the FDA updates these lists periodically.

Massachusetts-Specific Legal Status

Massachusetts does not have a statute that independently restricts or bans bremelanotide beyond federal prescription drug law. The legal status in the Commonwealth flows from three sources: the Massachusetts Board of Registration in Pharmacy, the Massachusetts Board of Registration in Medicine, and the state's adoption of federal scheduling through M.G.L. Chapter 94C.

Massachusetts Board of Registration in Pharmacy

The Board of Registration in Pharmacy regulates all dispensing of prescription drugs in Massachusetts under 247 CMR 9.00 [7]. A compounding pharmacy operating in Massachusetts must hold a resident pharmacy permit and comply with USP Chapter 795 (non-sterile) or USP Chapter 797 (sterile) standards, depending on whether bremelanotide is compounded as an injectable [8]. Injectable compounded bremelanotide requires sterile compounding compliance under USP 797, which sets strict requirements for beyond-use dates, environmental monitoring, and personnel training [8].

Massachusetts also requires pharmacies dispensing compounded preparations to maintain complete records and to dispense only upon receipt of a valid patient-specific prescription for 503A-type compounding [7]. Compounding for office use in Massachusetts is permitted in limited quantities consistent with federal 503A guidance.

Massachusetts Medical Practice Act and Prescribing Standards

Under M.G.L. Chapter 112, § 5, a physician licensed in Massachusetts may prescribe any FDA-approved drug within the bounds of their professional judgment, including for off-label uses. A licensed nurse practitioner or physician assistant with prescriptive authority may do the same within their scope of practice and collaborative agreement requirements [9].

Prescribing bremelanotide off-label to premenopausal men (for erectile dysfunction or low libido) is legal from a medical practice standpoint in Massachusetts, though it is not FDA-approved for those uses. The Massachusetts Board of Registration in Medicine expects prescribers to document clinical rationale for off-label use, especially for newer agents [9].

Controlled Substance Scheduling in Massachusetts

M.G.L. Chapter 94C mirrors the federal Controlled Substances Act scheduling. Because bremelanotide is not federally scheduled by the DEA, it is not scheduled under Chapter 94C either [4]. No Massachusetts-specific scheduling action has placed bremelanotide in a restricted category. Prescriptions do not require state-issued triplicate forms or mandatory PDMP (Prescription Drug Monitoring Program) entries in Massachusetts, though prescribers are encouraged to document all prescriptions in the Massachusetts PMP InterConnect system as a best practice [10].

How to Get PT-141 (Bremelanotide) in Massachusetts

Patients in Massachusetts have three practical pathways to obtain bremelanotide legally.

Pathway 1: Traditional In-Person Prescriber Visit

A gynecologist, urologist, sexual medicine specialist, or primary care physician licensed in Massachusetts can evaluate a patient, confirm a diagnosis of HSDD using validated tools such as the HSDD Screener for Women, and issue a written prescription for Vyleesi or compounded bremelanotide [11]. The prescription can be filled at any Massachusetts-licensed retail or compounding pharmacy.

The American College of Obstetricians and Gynecologists (ACOG) notes in its guidance on female sexual dysfunction: "Pharmacologic treatment options for HSDD include flibanserin and bremelanotide" [12]. ACOG recommends that clinicians screen for underlying causes (hormonal, psychological, relational) before initiating pharmacotherapy [12].

Pathway 2: Telehealth Prescribing

Massachusetts law permits telehealth encounters for the evaluation and management of sexual dysfunction. The state adopted a permanent telehealth framework in 2022 under M.G.L. Chapter 175, § 47BB, requiring insurers to cover telehealth services on par with in-person visits [13]. Because bremelanotide is not a controlled substance, it does not face the additional prescribing restrictions that apply to, for example, testosterone or Schedule III/IV medications under telehealth.

A telehealth clinician licensed in Massachusetts who conducts a synchronous audio-video evaluation, documents the HSDD diagnosis, reviews contraindications (cardiovascular history, uncontrolled hypertension), and issues a prescription is acting within Massachusetts law. The prescription can then be routed to a 503A compounding pharmacy or a retail pharmacy stocking Vyleesi.

Pathway 3: Out-of-State Compounding Pharmacies Shipping into Massachusetts

A 503A pharmacy licensed in another state may ship a compounded bremelanotide preparation to a Massachusetts patient if the pharmacy holds a non-resident pharmacy permit issued by the Massachusetts Board of Registration in Pharmacy under 247 CMR 6.00 [7]. The prescription must be patient-specific and issued by a Massachusetts-licensed prescriber or a prescriber licensed in the state where the patient is located at the time of the telehealth visit.

Patients should verify that any online pharmacy filling their prescription displays its Massachusetts non-resident permit number and provides a full label meeting 21 CFR 211.68 standards, including lot number, beyond-use date, and compounding pharmacy contact information [14].

Insurance Coverage in Massachusetts

Vyleesi is commercially available and covered by some private insurance plans in Massachusetts, but coverage is inconsistent. The drug does not have a mandatory coverage requirement under Massachusetts Chapter 58 (the state's 2006 health reform law) or ACA essential health benefits as currently defined. MassHealth (Massachusetts Medicaid) does not currently list bremelanotide as a covered benefit as of the most recent formulary update [15].

Compounded bremelanotide is almost never covered by insurance because compounded preparations are not FDA-approved finished products. Patients typically pay out-of-pocket, with costs ranging from approximately $60 to $250 per dose depending on the compounding pharmacy and concentration ordered.

Red Flags: What Makes a PT-141 Source Illegal in Massachusetts

Several online vendors sell "research-grade" bremelanotide without requiring a prescription. Purchasing from such vendors puts the buyer in legal jeopardy under the FD&C Act and creates safety risks from unverified purity and sterility.

Specifically illegal or high-risk scenarios include:

• Purchasing bremelanotide labeled "not for human use" from a research chemical supplier, which circumvents FDA drug approval requirements [5]
• Receiving a prescription from a prescriber who never conducted a real clinical evaluation (prescriptions issued after only a questionnaire with no clinician review do not meet Massachusetts standard of care) [9]
• Receiving compounded bremelanotide from a pharmacy that does not hold a Massachusetts non-resident permit [7]
• Importing bremelanotide from foreign sources, which may violate both the FD&C Act and U.S. Customs regulations [5]

The FDA Office of Criminal Investigations has prosecuted vendors of unapproved peptide products under 21 U.S.C. § 331(a) [5]. Massachusetts patients purchasing from gray-market sources may face civil forfeiture of the product and, in rare cases involving distribution, state-level prosecution under M.G.L. Chapter 94C § 32E for distribution of a counterfeit or unregistered drug.

Monitoring and Safety Considerations for Massachusetts Patients

Even when obtained legally, bremelanotide requires clinical oversight. The FDA label requires prescribers to assess blood pressure before initiating therapy and to advise patients not to use the drug if resting blood pressure exceeds 130/80 mmHg without antihypertensive treatment in place [1].

A 2019 review in the Journal of Sexual Medicine examining the Phase 3 trial safety data found that 12.7% of Reconnect participants experienced transient hypertension, and 1.0% discontinued due to cardiovascular adverse events [16]. Massachusetts prescribers should document pre-treatment blood pressure and reassess after the first dose.

Nausea management is a common clinical concern. The Reconnect trials reported nausea in 40.0% of bremelanotide-treated subjects vs. 1.3% placebo, with a median duration of approximately 1 hour [3]. Pre-treatment with oral ondansetron 4 mg roughly 30 minutes before the bremelanotide injection may reduce nausea severity, though this combination is off-label and should be discussed with a prescriber [17].

Hyperpigmentation is a less-discussed but real adverse effect. Long-term use (more than 8 weeks of continuous dosing) carries a risk of focal hyperpigmentation, particularly on the face, breasts, and gums, due to melanocortin receptor activation [1]. The FDA label recommends against using bremelanotide more than approximately once per 24 hours and advises discontinuation if hyperpigmentation develops [1].

Drug Interactions

Bremelanotide slows gastric emptying and may reduce the rate and extent of absorption of co-administered oral drugs. The FDA label specifically warns against co-administration with naltrexone (used in medications like Vivitrol or combined buprenorphion/naltrexone formulations) because of a pharmacodynamic interaction that may reduce naltrexone efficacy [1]. Massachusetts prescribers using medication-assisted treatment for opioid use disorder should be aware of this interaction when managing patients who may be candidates for bremelanotide [18].

Off-Label Use in Men

Several small studies have examined bremelanotide in men with erectile dysfunction refractory to PDE5 inhibitors. A Phase 2 trial published in the Journal of Urology (N=69) reported that 80.0% of men treated with bremelanotide achieved erections sufficient for intercourse vs. 32% placebo [19]. Massachusetts prescribers may prescribe bremelanotide off-label for men, but patients should understand this use lacks FDA approval and carries the same cardiovascular and nausea risk profile as documented in the female HSDD indication.

Summary of Legal Status by Scenario

| Scenario | Legal in Massachusetts? | |---|---| | Vyleesi (brand) with valid Rx from MA-licensed prescriber | Yes | | Compounded bremelanotide from MA-licensed 503A pharmacy with valid Rx | Yes, if not on FDA Bulks Prohibition List | | Compounded bremelanotide from out-of-state pharmacy with MA non-resident permit | Yes, with valid Rx | | "Research chemical" bremelanotide without Rx | No | | Imported bremelanotide from foreign source | No | | Off-label use in men with valid Rx | Legal to prescribe; not FDA-approved |

Patients who want a clear, defensible legal path should request a formal telehealth evaluation from a Massachusetts-licensed clinician and confirm that any compounding pharmacy filling their prescription holds a current Massachusetts non-resident pharmacy permit, which can be verified through the Massachusetts Board of Registration in Pharmacy license lookup tool at mass.gov [7].